Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Distinct structural classes of activating FOXA1 alterations in prostate cancer progression [RNA-Seq]

ABSTRACT: Expression profiles of 22RV1 prostate cancer cells following FOXA1 genetic engineering and or TLE3 knock-down

ORGANISM(S): Homo sapiens

PROVIDER: GSE123619 | GEO | 2018/12/12

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Distinct structural classes of activating FOXA1 alterations in prostate cancer progression [ChIP-Seq]

Project description:Chromatin binding profiles for FOXA1, AR, and TLE3 in prostate cancer cell lines with different FOXA1 genotypes. Full-length and truncated forms of FOXA1 are distinguished by C-terminal and N-terminal antibodies.

2018-12-12 | GSE123618 | GEO

Distinct structural classes of activating FOXA1 alterations in prostate cancer progression

Project description:Distinct structural classes of activating FOXA1 alterations in prostate cancer progression

| PRJNA509420 | ENA

Distinct structural classes of activating FOXA1 alterations in prostate cancer progression

Project description:This SuperSeries is composed of the SubSeries listed below.

2018-12-12 | GSE123625 | GEO

Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer.

Project description: Not available

| S-EPMC6661908 | biostudies-literature

Distinct structural classes of activating FOXA1 alterations in prostate cancer progression [ChIP-Seq]

Project description:Distinct structural classes of activating FOXA1 alterations in prostate cancer progression [ChIP-Seq]

| PRJNA509421 | ENA

Distinct structural classes of activating FOXA1 alterations in prostate cancer progression [RNA-Seq]

Project description:Distinct structural classes of activating FOXA1 alterations in prostate cancer progression [RNA-Seq]

| PRJNA509422 | ENA

Androgen receptor-independent function of FoxA1 in prostate cancer metastasis

Project description:FoxA1 has been shown critical for prostate development and prostate-specific gene expression regulation. In addition to its well-established role as an AR pioneering factor,several studies have recently revealed significant AR binding events in prostate cancer cells with FoxA1 knockdown. Furthermore, the role of FoxA1 itself in prostate cancer has not been carefully examined. Thus, it is important to understand the role of FoxA1 in prostate cancer and how it interacts with AR signaling. To address these questions, we generated engineered LNCaP cells with FoxA1 knockdown using shRNA or siRNA, 22RV1 cells with stable FoxA1 knockdown and PC3M cells with FoxA1 stable overexpression. We performed microarray analysis of these cells. We performed microarray analysis on LNCaP cells with FoxA1 knockdown using shRNA or siRNA, 22RV1 cells with stable FoxA1 knockdown and PC3M cells with FoxA1 stable overexpression

2013-04-05 | E-GEOD-37314 | biostudies-arrayexpress

We performed ChIP-seq for TLE3 in MDA-MB-453 cells with and without FOXA1 transient silencing (siFOXA1 vs siNS) to determine the requirement of FOXA1 for TLE3 binding.

Project description:The identification of mechanisms controlling breast tumor progression from less aggressive to highly metastatic disease should provide novel therapeutic targets for patients. Here we report the transcriptional corepressor, TLE3, as a critical regulator of cellular plasticity in breast cancer. TLE3 facilitates repression of genes associated with the highly aggressive basal-like breast cancer (BLBC) subtype within luminal cells. Additionally, maintenance of the luminal lineage is dependent on appropriate localization of TLE3 to its transcriptional targets which is mediated through interaction with FOXA1. Furthermore, the ability of TLE3 to repress BLBC transcription results in reduced metastatic capacity and aggressive cellular behaviors. Together our findings establish TLE3 as a critical transcriptional mediator of breast cancer aggressiveness, with TLE3 sustaining the more differentiated and less metastatic nature of luminal tumors through suppression of gene expression programs associated with BLBC.

2023-02-07 | GSE205862 | GEO

TLE3 drives luminal identity of breast cancer through transcriptional repression of FOXA1-target genes

2023-02-07 | GSE205356 | GEO

Androgen receptor-independent function of FoxA1 in prostate cancer metastasis

2013-04-05 | GSE37314 | GEO